X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Biodexa gain rights to develop and commercialize MLR-1023 (tolimidone), a selective activator of the enzyme lyn kinase and Phase II Ready Asset for Type 1 Diabetes.
Lead Product(s): Tolimidone
Therapeutic Area: Endocrinology Product Name: MLR-1023
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biodexa Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 27, 2023
Details:
MLR-1019 (armesocarb) is is the active enantiomer in mesocarb, a new class of drug for Parkinson’s Disease (PD) and represents the only drug to address both movement and non-movement symptoms of PD.
Lead Product(s): Armesocarb
Therapeutic Area: Neurology Product Name: MLR-1019
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2021
Details:
Adhera will license MLR-1023 (tolimidone) from Melior Pharma 1 for the purpose of developing a novel therapeutic for Type 1 diabetes. MLR-1023, a lyn kinase activator, which has shown exceptional clinical safety and tolerability in Phase 2a and Phase 2b Type 2 diabetes.
Lead Product(s): Tolimidone
Therapeutic Area: Endocrinology Product Name: MLR-102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Melior Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
